Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response includes several statements that are not supported by the provided FDA label excerpts, especially multiple discontinuation-related claims (cholesterol rebound timing, dose/duration/individual factors, and increased MI/stroke risk). Several safety assertions (e.g., increased blood sugar; antidepressant interactions) are also unsupported by the provided label sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
1 INDICATIONS AND USAGE (lipid-altering agent for hypercholesterolemia; adjunct to diet); 12.1 Mechanism of Action (cholesterol synthesis/inhibition; LDL cholesterol reduction discussed).
Lipitor works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (selective competitive inhibitor of HMG-CoA reductase; cholesterol synthesis in the liver).
Lipitor can cause side effects including muscle pain.
5.1 Skeletal Muscle (myopathy defined as muscle aches or muscle weakness; patients advised to report unexplained muscle pain/tenderness/weakness).
Lipitor can cause side effects including liver damage.
5.2 Liver Dysfunction (liver function test abnormalities/transaminase elevations); 6.2 Postmarketing Experience (hepatic failure listed).
Lipitor can interact with blood thinners.
7.7 Warfarin (no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin).
Lipitor can interact with antibiotics.
5.1 Skeletal Muscle (risk increased with certain drugs such as clarithromycin); 7.1 Strong Inhibitors of CYP 3A4 (clarithromycin increases atorvastatin AUC; dosing caution when exceeding 20 mg).
Unsupported Statements
Lipitor is used to reduce the risk of heart disease and stroke.
Not supported by the provided label excerpts; provided Indications text does not explicitly state an approval for reducing heart disease/stroke risk.
Lipitor can cause side effects including increased blood sugar levels.
No provided label excerpt supports increased blood sugar/glucose as an adverse effect.
Lipitor can interact with certain antidepressants.
No provided label excerpt supports antidepressant interactions.
Stopping Lipitor can cause cholesterol levels to rise.
No provided label excerpt addresses cholesterol rebound after discontinuation.
Stopping Lipitor can increase the risk of heart disease and stroke.
No provided label excerpt addresses increased cardiovascular event risk after discontinuation.
Stopping Lipitor can increase the risk of heart attack and stroke, particularly in individuals with pre-existing cardiovascular conditions.
No provided label excerpt supports event-risk modification by discontinuation or pre-existing cardiovascular conditions.
Some individuals may experience muscle pain and weakness after stopping Lipitor.
No provided label excerpt addresses muscle symptoms after discontinuation.
Muscle pain and weakness after stopping Lipitor may occur particularly if the medication was taken for an extended period.
No provided label excerpt supports discontinuation-related symptom timing or dependence on treatment duration.
Stopping Lipitor can cause liver damage in some individuals.
Provided excerpts discuss liver function test abnormalities during therapy and hepatic failure as an adverse reaction, but do not support discontinuation-specific liver damage claims.
Stopping Lipitor can cause liver damage particularly in individuals with pre-existing liver disease.
No provided label excerpt supports discontinuation-specific liver damage risk stratified by pre-existing liver disease.
When you stop taking Lipitor, the body will begin to produce more cholesterol.
No provided label excerpt addresses physiologic cholesterol production changes after stopping.
The extent to which cholesterol levels rise after stopping Lipitor depends on factors including duration of treatment.
No provided label excerpt addresses cholesterol rise after discontinuation or influencing factors.
The longer you take Lipitor, the more your body may adapt to the medication.
No provided label excerpt supports a label basis for 'adaptation' and its relationship to discontinuation outcomes.
After stopping Lipitor, longer duration of treatment may result in a greater increase in cholesterol levels.
No provided label excerpt supports discontinuation-related increase in cholesterol or dependence on duration.
Higher doses of Lipitor may be more likely to cause a significant increase in cholesterol levels when discontinued.
No provided label excerpt supports dose-dependent cholesterol rebound after discontinuation.
Individual factors such as age, weight, and overall health can influence the extent to which cholesterol levels rise when Lipitor is stopped.
No provided label excerpt supports discontinuation-related cholesterol changes or how age/weight/overall health modify them.
Cholesterol levels may begin to rise within a few weeks to a few months after stopping Lipitor.
No provided label excerpt provides timing for cholesterol changes after discontinuation.
Stopping Lipitor may increase the risk of heart disease and stroke by causing cholesterol levels to rise.
No provided label excerpt supports a causal/discontinuation-mediated increase in cardiovascular risk via cholesterol rise.
Lipitor can interact with antibiotics.
Partially supported; however the blanket claim is broader than the provided label excerpts, which specifically support certain drugs (e.g., clarithromycin) rather than antibiotics generally.
Lipitor can interact with blood thinners.
Partially supported but may be misleading as a general interaction claim: provided excerpt for warfarin states no clinically significant effect on prothrombin time.
Contradictions
Important Omissions
Boxed warning/major class warnings (not included in provided label excerpts) and critical contraindication details beyond active liver disease were not addressed in the AI claims. (This evaluation focuses only on provided AI claims; however missing label elements reduce overall on-label fidelity.)
Importance:
Moderate
Dose/administration specifics and monitoring recommendations (e.g., liver function test schedule; skeletal muscle monitoring) were not included to contextualize safety claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported discontinuation-related cardiovascular risk and cholesterol rebound timing could mislead patient decision-making; unsupported additional safety/interactions claims (e.g., increased blood sugar; antidepressant interactions) also reduce label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple discontinuation-related assertions and several safety/interactions claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rewrite discontinuation-related cholesterol and cardiovascular event risk statements unless supported by provided label text; limit interaction and adverse reaction statements to those explicitly supported in the supplied label excerpts (e.g., skeletal muscle risk with certain interacting drugs; liver test abnormalities during therapy).